Endosense

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company has conducted numerous clinical studies and has shown that using contact force during ablation can reduce procedure time (1), as well as PV gaps at 3-month invasive follow-up (2).

The company’s flagship product is the TactiCath Quartz®, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure.

Prior to force-sensing – which Endosense pioneered in catheter ablation – the physicians had to estimate the force applied during ablation. If too much force was applied, there was a risk of perforating the heart wall, if too little force was applied, there was a risk of recurrence; the patient needing a second treatment.

(1) Force controlled RF ablation increases Effectivity for AF ablation using PV isolation J. Schreieck et al., Tübingen, Germany – Clin Res Cardiol 101, Suppl 1, April 2012, P660

(2) Contact Force, FTI and Lesion continuity are critical to improve durable PV isolation: EFFICAS II results J Kautzner et al. – Heart Rhythm Society, May 2012, Boston USA

Company’s Keywords:

medtech, catheter ablation, atrial fibrillation, force sensing